US40637H1095
© PR Newswire
08.12.2025
HALO
LISTED
NASDAQ
Jim Lang Elected to Halozyme's Board of Directors
News Preview
SAN DIEGO, Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 years of executive leadership experience in healthcare, life sciences, business services and data analytics."Jim brings extensive experience in building and...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
HALO
LISTED
NASDAQ
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
News Preview
SAN DIEGO, Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck to refrain from distributing and offering Keytruda SC in Germany.The Munich Regional Court's 7th Civil Division found that there is imminent infringem...
Themefolio
Profiler
Peergroup
© PR Newswire
25.11.2025
HALO
LISTED
NASDAQ
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
News Preview
SAN DIEGO, Nov. 25, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the 8th Annual Evercore Healthcare Conference.The presentation is scheduled for Tuesday, December 2 at 10:20am PT / 1:20pm ET.A liv...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
18.11.2025
HALO
LISTED
NASDAQ
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
News Preview
Royalty revenue contribution expected to begin as early as 2030
Initial partner targets include derisked MoAs that are approved blockbusters today
Highly scalable licensing model and long duration IP into 2040s...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
17.11.2025
HALO
LISTED
NASDAQ
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
News Preview
SAN DIEGO and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 17, 2025 /PRNewswire/ -- Merus N.V. (Nasdaq: MRUS) ("Merus"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), and Halozyme Therapeutics, Inc. (Na...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2025
HALO
LISTED
NASDAQ
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
News Preview
DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology
SAN DIEGO, Nov. 7, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson received U.S. Food and Drug Administratio...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
HALO
LISTED
NASDAQ
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
News Preview
Royalty Revenue Increased 52% YOY to Record $236 million and Total Revenue Increased 22% YOY to Record $354 million
Net Income Increased 28% YOY to $175 million; Adjusted EBITDA Increased 35% YOY to $248 million; GAAP Diluted EPS Increased 36% YOY to $1.43; Non-...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2025
HALO
LISTED
NASDAQ
Halozyme to Report Third Quarter 2025 Financial and Operating Results
News Preview
SAN DIEGO, Oct. 21, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2025 financial and operating results on Monday, November 3, 2025, following the close of trading.
Halozyme will host a conference call on Monday, Novem...
Themefolio
Profiler
Peergroup
© PR Newswire
28.08.2025
HALO
LISTED
NASDAQ
Halozyme to Participate at Upcoming Investor Conferences
News Preview
SAN DIEGO, Aug. 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate Communications, are scheduled to participate and host investor meetings at the following investor conferences.
Details...
Themefolio
Profiler
Peergroup
© PR Newswire
23.07.2025
HALO
LISTED
NASDAQ
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
News Preview
DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology
Approval represents critical advancement in early intervention for multiple myeloma
SAN DIEGO, July 23, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company,...
Themefolio
Profiler
Peergroup
© PR Newswire
22.07.2025
HALO
LISTED
NASDAQ
Halozyme to Report Second Quarter 2025 Financial and Operating Results
News Preview
SAN DIEGO, July 22, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and operating results on Tuesday, August 5, 2025, following the close of trading.
Halozyme will host a conference call on Tuesday, August 5, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss...
Themefolio
Profiler
Peergroup
© PR Newswire
30.06.2025
HALO
LISTED
NASDAQ
Halozyme Therapeutics Added to Russell 1000® Index
News Preview
SAN DIEGO, June 30, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that it has been added to the U.S. large-cap Russell 1000® Index, effective after market close on June 27th, as part of the 2025 FTSE Russell indexes annual reconstitution.
The Russell 1000® Index includes approximately 1,000 of the larg...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
20.06.2025
HALO
LISTED
NASDAQ
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
News Preview
SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional
SAN DIEGO, June 20, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa...
Themefolio
Profiler
Peergroup
© PR Newswire
28.05.2025
HALO
LISTED
NASDAQ
Halozyme to Participate at Upcoming Investor Conferences
News Preview
SAN DIEGO, May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to participate and host investor meetings at the following investor conferences.
Details on the Company's participation are as follows:
Event:
Benchmark 2025 Hea...
Themefolio
Profiler
Peergroup
© PR Newswire
28.05.2025
HALO
LISTED
NASDAQ
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
News Preview
Opdivo® is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union
SAN DIEGO, May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received European Commission (EC) approval of a new Opdivo® (nivolumab) subcutaneous formulation developed wit...
Themefolio
Profiler
Peergroup
© PR Newswire
06.05.2025
HALO
LISTED
NASDAQ
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
News Preview
Announcing New $250M Share Repurchase
Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million
Net Income Increased 54% YOY to $118 million; Adjusted EBITDA Increased 40% YOY to $162 million; GAAP Diluted EPS Increased 55% YOY to $0.93; non-GAAP Diluted EPS Increased 41% YOY to $1.111
Raising 2025 Fi...
Themefolio
Profiler
Peergroup
© PR Newswire
05.05.2025
HALO
LISTED
NASDAQ
Halozyme to Participate in the BofA Securities 2025 Healthcare Conference
News Preview
SAN DIEGO, May 5, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the BofA Securities 2025 Healthcare Conference.
The presentation is scheduled for Tuesday, May 13 at 4:20pm PT / 7:20pm ET.
A live a...
Themefolio
Profiler
Peergroup
© PR Newswire
28.04.2025
HALO
LISTED
NASDAQ
Halozyme to Report First Quarter 2025 Financial and Operating Results
News Preview
SAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, following the close of trading.
Halozyme will host a conference call on Tuesday, May 6, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the r...
Themefolio
Profiler
Peergroup
© PR Newswire
28.04.2025
HALO
LISTED
NASDAQ
Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
News Preview
European Commission (EC) decision on marketing authorization application expected within approximately two months
SAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Med...
Themefolio
Profiler
Peergroup
© PR Newswire
24.04.2025
HALO
LISTED
NASDAQ
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation
News Preview
Complaint filed in New Jersey alleges Merck uses Halozyme's patented MDASE technology to develop SC Keytruda
Halozyme is seeking damages and injunctive relief to stop the infringement
SAN DIEGO, April 24, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronida...
Themefolio
Profiler
Peergroup
© PR Newswire
11.04.2025
HALO
LISTED
NASDAQ
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
News Preview
SAN DIEGO, April 10, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART® Hytrulo prefilled syringe for self-injection (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myastheni...
Themefolio
Profiler
Peergroup
© PR Newswire
09.04.2025
HALO
LISTED
NASDAQ
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
News Preview
Subcutaneous DARZALEX® is co-formulated with Halozyme's ENHANZE® drug delivery technology
SAN DIEGO, April 9, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval for an indication extension of DAR...
Themefolio
Profiler
Peergroup
© PR Newswire
07.04.2025
HALO
LISTED
NASDAQ
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
News Preview
SAN DIEGO, April 7, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, has received European Commission (EC) marketing authorization of the subcutaneous (SC) formulation of RYBREVANT® (amivantamab), in combination with LAZCLUZE® (lazertin...
Themefolio
Profiler
Peergroup
© PR Newswire
31.03.2025
HALO
LISTED
NASDAQ
Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications
News Preview
A decision on the European marketing authorization extension for the subcutaneous formulation of Opdivo is expected by June 2, 2025
SAN DIEGO, March 31, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received a positive opinion from the Committee for Medicinal Products for Huma...
Themefolio
Profiler
Peergroup
© PR Newswire
26.02.2025
HALO
LISTED
NASDAQ
Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
News Preview
SAN DIEGO, Feb. 26, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the TD Cowen 45th Annual Healthcare Conference.
The presentation is scheduled for Wednesday, March 5 at 8:50am PT / 11:50am ET.
A...
Themefolio
Profiler
Peergroup
© PR Newswire
18.02.2025
HALO
LISTED
NASDAQ
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS
News Preview
Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 million
Fourth Quarter Net Income Increased 60% YOY to $137 million; Adjusted EBITDA Increased 61% YOY to $196 million; GAAP EPS Increased 63% YOY to $1.06; non-GAAP EPS Increased 54% YOY to $1.261
Record Full Year 2024 Total Revenue Incre...
Themefolio
Profiler
Peergroup
© PR Newswire
04.02.2025
HALO
LISTED
NASDAQ
Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results
News Preview
SAN DIEGO, Feb. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 financial and operating results on Tuesday, February 18, 2025, following the close of trading.
Halozyme will host a conference call on Tuesday, February 18, 2025 at 1:30 p.m. PT/4:30...
Themefolio
Profiler
Peergroup
© PR Newswire
03.02.2025
HALO
LISTED
NASDAQ
CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
News Preview
SAN DIEGO, Feb. 3, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending an extension of marketing autho...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
HALO
LISTED
NASDAQ
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
News Preview
Reports Preliminary 2024 Unaudited Estimated Ranges Consistent with Previous Financial Guidance
Raises 2025 Financial Guidance Ranges for Total Revenue to $1,150 - $1,225 million, Representing YoY Growth of 16% - 23%, Adjusted EBITDA of $755 - $805 million, Representing YoY Growth of 24% - 32%, and non-GAAP Diluted EPS of $4.95 - $5.35, Represen...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2025
HALO
LISTED
NASDAQ
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
News Preview
SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 8, 2025, at 5:30 a.m. PT / 8:30 a.m. ET.
On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide pre...
Themefolio
Profiler
Peergroup
© PR Newswire
30.12.2024
HALO
LISTED
NASDAQ
Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
News Preview
SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Takeda received regulatory approval for HYQVIA® [Immune Globulin Infusion 10% (Human) with Halozyme's Recombinant Human Hyaluronidase] by the Japanese Ministry of Health, Labour and Welfare (MHLW) for patients with agammaglobulinemi...
Themefolio
Profiler
Peergroup
© PR Newswire
30.12.2024
HALO
LISTED
NASDAQ
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
News Preview
SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated with Halozyme's ENHANZE® drug delivery technology, was granted regulatory approval by Japan's Ministry of Health, Labour and Welfare (MHLW) for adul...
Themefolio
Profiler
Peergroup
© PR Newswire
30.12.2024
HALO
LISTED
NASDAQ
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications
News Preview
Opdivo Qvantig represents the first and only subcutaneously administered PD-1 inhibitor
Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to IV Opdivo in the Phase 3 CheckMate-67T trial
SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol...
Themefolio
Profiler
Peergroup
© PR Newswire
27.11.2024
HALO
LISTED
NASDAQ
Halozyme to Present at Upcoming Investor Conferences
News Preview
SAN DIEGO, Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the executive leadership team are scheduled to present and host investor meetings at the following investor conferences.
Details on the presentations are as follows:
Event:
Piper Sandler 36th Annual Healthcare Conferen...
Themefolio
Profiler
Peergroup
© PR Newswire
22.11.2024
HALO
LISTED
NASDAQ
Halozyme nimmt Vorschlag über Zusammenschluss mit Evotec aufgrund fehlender Gesprächsbereitschaft von Evotec zurück
News Preview
SAN DIEGO, 22. November 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) („Halozyme" oder das „Unternehmen") hat heute bekannt gegeben, dass es sein unverbindliches Angebot zum Zusammenschluss mit der Evotec SE (NASDAQ: EVO) („Evotec") für einen Barpreis in Höhe von 11,00 € pro Aktie zurückgenommen hat. Das Angebot entsprach einem...
Themefolio
Profiler
Peergroup
© PR Newswire
22.11.2024
HALO
LISTED
NASDAQ
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
News Preview
SAN DIEGO, Nov. 22, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion.
Helen Torley, president and chief executive...
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2024
HALO
LISTED
NASDAQ
Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
News Preview
Would establish an innovative pharma services company with capabilities spanning drug discovery and development, biologic manufacturing and drug delivery technologies
Would meaningfully diversify, scale and extend Halozyme's revenue and adjusted EBITDA well into the next decade and beyond
All-cash transaction would be funded by cash on hand and n...
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2024
HALO
LISTED
NASDAQ
Halozyme stellt weitere Informationen zum nicht bindenden Vorschlag eines Zusammenschlusses mit Evotec zur Verfügung
News Preview
Halozyme Therapeutics, Inc.
Ein Zusammenschluss würde ein innovatives Pharma-Dienstleistungsunternehmen mit Expertise in den Bereichen Wirkstoffforschung und -entwicklung, Herstellung von Biologika sowie Arzneimittelverabreichungstechnologien schaffenEin Zusammenschluss würde Umsatz- und bereinigtes EBITDA-Wachstum von Halozyme erheblich diversi...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2024
HALO
LISTED
NASDAQ
Halozyme bestätigt Vorschlag des Zusammenschlusses mit Evotec für 11,00 € pro Aktie im Rahmen eines Barangebots
News Preview
Ein Zusammenschluss würde ein globales und innovatives Dienstleistungsunternehmen schaffen – mit einem einzigartigen Spektrum unterschiedlichster Technologien, einer vielfältigen Produktpipeline und einem branchenführenden Team
SAN DIEGO, 14. November 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) („Halozyme" oder das „Unternehm...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2024
HALO
LISTED
NASDAQ
Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction
News Preview
Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team
SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
HALO
LISTED
NASDAQ
HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS
News Preview
Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million
Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 million
GAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% YOY to $1.271
Raised 2024 Financial Guidance Ranges for Total Re...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2024
HALO
LISTED
NASDAQ
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
News Preview
Company Projects No Impact on U.S. or European Royalty Revenues from DARZALEX FASPRO® and SC through 2032
Reiterates 2024 Royalty Revenue Guidance of $520-555 million and Expectations to Generate >$1 billion in 2027
Conference Call Scheduled Today, Thursday, October 24 at 5:30am PT/8:30am ET
SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Halozyme Th...
Themefolio
Profiler
Peergroup
© PR Newswire
23.10.2024
HALO
LISTED
NASDAQ
Halozyme to Report Third Quarter 2024 Financial and Operating Results
News Preview
SAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and operating results on Thursday, October 31, 2024, following the close of trading.
Halozyme will host a conference call on Thursday, October 31, 2024 at 1:30 p.m. PT/4:30 p.m. ET to di...
Themefolio
Profiler
Peergroup
© PR Newswire
03.10.2024
HALO
LISTED
NASDAQ
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®
News Preview
Four new targets nominated for total of six nominated targets, including FcRn (VYVGART® Hytrulo), for ENHANZE® drug delivery technology
Halozyme to receive total upfront payment of $30 million for exclusive rights to targets
SAN DIEGO, Oct. 3, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that argenx has nominate...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2024
HALO
LISTED
NASDAQ
Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm
News Preview
Kaskela Law LLC announces that it is investigating Halozyme Therapeutics, Inc. (“Halozyme”) (NASDAQ: HALO) on behalf of the company’s shareholders.
The investigation seeks to determine whether Halozyme and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties to the company’s investors in connecti...
Themefolio
Profiler
Peergroup
© PR Newswire
13.09.2024
HALO
LISTED
NASDAQ
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis
News Preview
OCREVUS ZUNOVO™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints
SAN DIEGO, Sept. 13, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Roche received U.S. Food and Drug Administration (FDA) approval for OCREVUS ZUNOVO™ (ocrelizumab and hyaluron...
Themefolio
Profiler
Peergroup
© PR Newswire
13.09.2024
HALO
LISTED
NASDAQ
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer
News Preview
FDA approval marks first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
SAN DIEGO, Sept. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received U.S. Food and Drug Administration (FDA) approval for Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs) with Halozyme's ENHANZE...
Themefolio
Profiler
Peergroup
© PR Newswire
28.08.2024
HALO
LISTED
NASDAQ
Halozyme to Present at Upcoming Investor Conferences
News Preview
SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate Communications, are scheduled to present and host investor meetings at the following investor conferences.
Details of...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
